Rondoraptivon pegol (BT200)

Rondoraptivon pegol (BT200)


Zhu et al, J Thromb Haemost. 2020 Feb 3.

BT200 is a PEGylated aptamer that binds A1 domain of human VWF

Basic pharmacology of BT200

BT200 Phase 1 program (NCT04103034)

BT200 Phase 2 pilot study in hereditary bleeding disorders (NCT04677803)


© 2023 Guardian Therapeutics. All rights reserved.

Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.

Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:

Business Development Inquiries: